NTLA · Intellia Therapeutics
AI read · Good for NTLA
The AI's read
The HAE results give Intellia a path toward a possible U.S. launch in the first half of next year. FDA approval is not certain, and Nexi trials face a liver-safety concern that the company is addressing with updated trial rules. Intellia also said its cash should fund operations into 2028, excluding product sales. That helps, though the company reported a quarterly loss of $106.6 million and higher costs to prepare for sales.